IKT - NASDAQ

Inhibikase Therapeutics, Inc.

IKT·NASDAQ

$1.70

-0.88%

HealthcareBiotechnology

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$223.80M

EPS-0.4900

P/E Ratio-3.46

Earnings Date08/13/2026

181.20M

Assets

84%

3Y+627.0%

5Y+1126.0%

10Y+111118.0%

8.30M

Total Liabilities

122%

3Y+113.0%

5Y+66.0%

10Y+448.0%

172.90M

Total Equity

82%

3Y+722.0%

5Y+1667.0%

10Y-12891.0%

Inhibikase Therapeutics, Inc. Funding & Solvency Profile

IKT · NASDAQ

Current Assets

Cash & Cash Equivalents139.22M

Net Receivables0.00

Inventory0.00

Other Current Assets1.35M

Total Current Assets180 M

Non-Current Assets

Property, Plant & Equipment0.00

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets1.10M

Total Non-Current Assets1 M

Total Assets

181.20M

Financial Health Analysis

Current Ratio

21.70x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.05x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

172 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

99% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Inhibikase Therapeutics, Inc. Balance Sheet

IKT • NASDAQ

Inhibikase Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	139.2M	56.5M	9.2M	7.2M	40.8M	14M	18.5K	379.6K	16.7K	12K
Short-Term Investments	39.5M	41.1M	4.1M	15.9M	0.0	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	178.8M	97.5M	13.3M	23.1M	40.8M	14M	18.5K	379.6K	16.7K	12K
Net Receivables	0.0	0.0	0.0	39.9K	110.1K	0.0	0.0	472.9K	180.8K	66.9K
Accounts Receivables	0.0	0.0	0.0	39.9K	110.1K	0.0	0.0	472.9K	180.8K	66.9K
Prepaids	0.0	801.5K	219.8K	163.5K	1.5M	774.4K	0.0	399.1K	625.0	1.3K
Other Current Assets	1.3M	106.3K	739.2K	1.1M	107K	54.8K	16.9K	0.0	0.0	0.0
Total Current Assets	180.1M	98.5M	14.2M	24.4M	42.5M	14.8M	35.4K	1.3M	198.1K	80.2K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	0.0	148.5K	295.6K	565.2K	0.0	0.0	0.0	0.0	0.0	0.0
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	87.1K	0.0
Other Non-Current Assets	1.1M	0.0	0.0	0.0	0.0	0.0	2.9K	1.6M	0.0	82.8K
Total Non-Current Assets	1.1M	148.5K	295.6K	565.2K	0.0	0.0	2.9K	1.6M	87.1K	82.8K
Total Assets	181.2M	98.6M	14.5M	24.9M	42.5M	14.8M	38.3K	2.8M	285.2K	162.9K
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.2M	943K	646.8K	1.2M	1.1M	1.7M	1M	954.2K	353.5K	431.8K
Accounts Payable	1.2M	943K	646.8K	1.2M	1.1M	1.7M	1M	954.2K	353.5K	431.8K
Accrued Expenses	0.0	2.7M	1.6M	2.4M	2.7M	632.9K	1.7M	2.2M	907.1K	753.9K
Short Term Debt	0.0	0.0	381.8K	0.0	248.9K	42.5K	98.4K	233.7K	460K	328.9K
Capital Lease Obligations (Current)	0.0	110.5K	150.1K	145.8K	0.0	0.0	0.0	0.0	-5.6K	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	2.3M	1.4M	262.4K	5.6K	0.0
Other Current Liabilities	7.1M	0.0	635.5K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Current Liabilities	8.3M	3.7M	3.4M	3.7M	4.1M	4.7M	4.3M	3.6M	1.7M	1.5M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	276.5K	275.4K	0.0	0.0	0.0
Total Non-Current Liabilities	0.0	0.0	90.1K	205.5K	0.0	276.5K	275.4K	1.5M	0.0	0.0
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.5M	0.0	0.0
Capital Lease Obligations	0.0	110.5K	240.2K	351.3K	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	8.3M	3.7M	3.5M	3.9M	4.1M	5M	4.5M	3.6M	1.7M	1.5M
SHAREHOLDERS' EQUITY
Common Stock	131.7K	69.4K	6.2K	4.2K	25.2K	10.1K	8.2K	8.2K	8.9K	8.9K
Additional Paid-In Capital	315.4M	189.3M	77.9M	68.8M	68.2M	24.8M	7.7M	5.7M	2.9M	2.5M
Retained Earnings	-142.7M	-94.4M	-66.9M	-47.9M	-29.8M	-15M	-12.2M	-6.5M	-4.3M	-3.9M
Accumulated Other Comprehensive Income/Loss	21.8K	-37.2K	877.0	104.7K	0.0	0.0	0.0	0.0	0.0	0.0
Other Total Stockholders' Equity	0.0	777.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Stockholders' Equity	172.9M	94.9M	11M	21M	38.4M	9.8M	-4.5M	-778K	-1.4M	-1.4M
Total Equity	172.9M	94.9M	11M	21M	38.4M	9.8M	-4.5M	-778K	-1.4M	-1.4M
SUMMARY
Total Liabilities & Equity	181.2M	98.6M	14.5M	24.9M	42.5M	14.8M	38.3K	2.8M	285.2K	162.9K
Total Investments	39.5M	41.1M	4.1M	15.9M	0.0	0.0	0.0	0.0	87.1K	0.0
Total Debt	0.0	110.5K	622K	351.3K	248.9K	319K	373.8K	233.7K	460K	328.9K
Net Debt	-139.2M	-56.4M	-8.5M	-6.8M	-40.5M	-13.6M	355.3K	-145.8K	443.3K	316.9K
Shares Outstanding	74,516,635	74,516,635	74,516,635	74,516,635	74,516,635	74,516,635	74,516,635	74,516,635	74,516,635	74,516,635

SEC Filings

IKT - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 12, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 12, 2026	May 12, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 30, 2026	June 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 07, 2026	April 07, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 26, 2026	March 26, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 19, 2025	December 19, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 21, 2025	November 20, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 20, 2025	November 20, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 14, 2025	November 14, 2025	2025	View Filing

Showing 1 to 10 of 113 filings

Related Guides

Blog Categories

Continue your IKT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.